or Try an Advanced Search...

    Neuropathic Pain Stocks List

    Symbol Grade Name % Change
    ASRT D Assertio Therapeutics, Inc. -9.02
    BIIB D Biogen Idec Inc. -1.76
    BLRX F BioLineRx Ltd. -3.89
    CHRO F Chromocell Therapeutics Corporation 0.00
    ELYM B Eliem Therapeutics, Inc 8.79
    NKTR B Nektar Therapeutics -9.39
    RVNC F Revance Therapeutics, Inc. 3.66
    XENE D Xenon Pharmaceuticals Inc. 0.12
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Pain Biotechnology Biopharmaceutical Acute Pain Analgesics Chemical Compounds Chronic Pain Clinical Development Drugs Erythromelalgia Immunology Migraine Opioids Organic Compounds Peripheral Neuropathy Pharmaceutical Pharmacology Postherpetic Neuralgia Acne Acute Myeloid Leukemia

    Related ETFs - A few ETFs which own one or more of the above listed Neuropathic Pain stocks.

    Symbol Grade Name Weight
    IBRN D iShares Neuroscience and Healthcare ETF 8.62
    PBE D PowerShares Dynamic Biotech & Genome 7.34
    BIS D ProShares UltraShort Nasdaq Biotechnology 6.6
    BBH C Market Vectors Biotech ETF 4.51
    DIP A BTD Capital Fund 4.41
    View all Neuropathic Pain ETFs...
    Compare ETFs
    Compare BIS to BBH Compare BIS to DIP Compare IBRN to BIS

        Neuropathic Pain Stocks Recent News

        Date Stock Title
        May 7 ASRT Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call Transcript
        May 7 ASRT Q1 2024 Assertio Holdings Inc Earnings Call
        May 7 ASRT Assertio Holdings Inc (ASRT) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
        May 6 ASRT Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript
        May 6 ASRT Assertio Holdings Inc (ASRT) Surpasses Revenue Estimates But Reports Wider Loss in Q1 2024
        May 6 ASRT Assertio Holdings Non-GAAP EPS of $0.04 beats by $0.05, revenue of $31.9M beats by $2.39M
        May 6 ASRT Assertio Reports First Quarter 2024 Financial Results
        May 6 XENE What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
        May 6 BLRX BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
        May 4 BIIB Morgan Stanley’s Top 15 Stock Picks for 2024
        May 3 ASRT Assertio Holdings Q1 2024 Earnings Preview
        May 2 NKTR Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
        May 2 RVNC Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
        May 2 XENE Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
        May 2 BIIB Biogen Reports Progress on Corporate Responsibility Priorities
        May 1 BIIB Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
        Apr 30 BIIB Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Pain Biotechnology Biopharmaceutical Acute Pain Analgesics Chemical Compounds Chronic Pain Clinical Development Drugs Erythromelalgia Immunology Migraine Opioids Organic Compounds Peripheral Neuropathy Pharmaceutical Pharmacology Postherpetic Neuralgia Acne Acute Myeloid Leukemia
        Neuropathic Pain

        Neuropathic pain is a type of chronic pain that is caused by damage or disease affecting the somatosensory nervous system. It is often described as a shooting, burning, or tingling sensation. Neuropathic pain can be caused by a variety of conditions, including diabetes, multiple sclerosis, shingles, and spinal cord injury.

        Browse All Tags